- Healthcare Professionals
- Research
- Clinical trials
- takeda tak-573-1501
Haematology
Haematology
2024-03-04T00:00:00.000+00:00
Takeda TAK-573-1501
Takeda TAK-573-1501
Haematology
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Trial overview
Description
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma.
Study details
For detailed information on this trial, please click here
Trial status
Open but closed to recruitment
Location
Oxford Milton Keynes
:::
Priniciple Investigator
